Digestive and breast cancer patients managed during the first wave of COVID-19 pandemic: Short and middle term outcomes

Table 1 Patient demographics and number of comorbidities by cancer type, n (%)

		Colorectal	HBP	OG	Breast
Total number		53 (100)	13 (100)	9 (100)	20 (100)
Age (yr)	40-49	3 (5.7)	2 (15.4)		5 (25.0)
	50-59	3 (5.7)	2 (15.4)		8 (40.0)
	60-69	13 (24.5)	5 (38.5)	5 (55.6)	3 (15.0)
	70-79	22 (41.5)	3 (23.1)	3 (33.3)	4 (20.0)
	80-89	11 (20.8)	1 (7.7)	1 (11.1)
	90-99	1 (1.9)
Sex	Female	18 (34)	7 (53.8)	2 (22.2)	19 (95.0)
	Male	35 (66)	6 (46.2)	7 (77.8)	1 (5.0)
ECOG perfor-mance score	0	13 (24.5)	5 (38.5)	3 (33.3)	19 (95.0)
	1	21 (39.6)	6 (46.2)	4 (44.4)	1 (5.0)
	2	17 (32.1)	2 (15.4)	2 (22.2)
	3	2 (3.8)
ASA	I	7 (13.2)	1 (7.7)	0	4 (20.0)
	II	25 (47.2)	6 (46.2)	6 (66.7)	13 (65.0)
	III	17 (32.1)	5 (38.5)	2 (22.2)	3 (15.0)
	IV	4 /7.5)	1 (7.7)	1 (11.1)
BMI	< 18.5	0	1 (7.7)
	18.5-24.9	10 (18.9)	4 (30.8)	3 (33.3)	7 (35.0)
	25-29.9	24 (45.3)	5 (38.5)	5 (55.6)	8 (40.0)
	30-34.9	15 (28.3)	1 (7.7)	1 (11.1)	1 (5.0)
	35-39.9	4 (28.3)	1 (7.7)		3 (15.0)
	≥ 40	0	1 (7.7)		1 (5.0)
Number of comorbidities	Mean (SD), range	3.13 (1.34) 1-6	2.85 (1.4), 1-5	3 (1.22) 1-5	1.85 (1.14) 0-4

ECOG: Eastern cooperative oncology group; ASA: American society of anesthesiology; BMI: Body mass index; HBP: Hepato-Bilio-Pancreatic; OG: Oesophago-Gastric.